AKT1 and breast carcinoma: The current study concluded that the novel ruthenium-fluvastatin complex is capable of downregulating SNCG expression associated with breast carcinoma cell line regulation by inhibiting cell proliferation and inducing apoptosis by triggering the cascade of PI3K/Akt/mTOR/VEGF/MMP9.